A Clinico-Bacteriological Study and Effect of Stress Ulcer Prophylaxis on Occurrence of Ventilator Associated Pneumonia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00702871 |
Recruitment Status :
Completed
First Posted : June 20, 2008
Last Update Posted : June 20, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Objective of this study was to determine incidence, risk factors, etiological micro-organisms and their antimicrobial susceptibility pattern and outcome of VAP; and to study effect of ranitidine vs. sucralfate, used for stress ulcer prophylaxis, on gastric colonization and on occurrence of VAP.
Methods: Design: Prospective randomized study. Setting: ICUs of Medicine Department and Anesthesiology Department, Maulana Azad Medical College and Lok Nayak Hospital, University of Delhi, New Delhi. Patients: 50 patients of age more than 12 years, who had been on ventilator for more than 48 hrs. Intervention: Endotracheal Aspirate and blood sample of all patients were cultured to determine micro-organisms causing VAP and their antimicrobial susceptibility pattern. Patients were divided into 2 groups on random basis. The first group was given ranitidine for stress ulcer prophylaxis while the second was given sucralfate. Thereafter, difference in gastric colonization (on basis of quantitative culture of nasogastric aspirate) and on occurrence of VAP in both the groups was compared.
Study Hypothesis: Study was designed to create data about Ventilator associated pneumonia in developing countries like India. This data is crucial for providing information for deciding future guidelines for treatment of and prevention of Ventilator associated pneumonia. Further to test the hypothesis that H2 blockers, by virtue of raising gastric Ph, increase gastric colonization by pathogenic organism and increase incidence of Ventilator associated pneumonia; patients were divided into two groups on random basis, as described above.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ventilator Associated Pneumonia Etiological Organisms Antimicrobial Drug Susceptibility Pattern Stress Ulcer Prophylaxis | Drug: Ranitidine Drug: Sucralfate | Phase 4 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 50 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Clinico-Bacteriological Study and Effect of Stress Ulcer Prophylaxis on Occurrence of Ventilator Associated Pneumonia: a Randomized Prospective Study |
Study Start Date : | March 2005 |
Actual Primary Completion Date : | April 2006 |
Actual Study Completion Date : | April 2006 |

Arm | Intervention/treatment |
---|---|
Active Comparator: 1
Arm 1 was given Injection Ranitidine 50mg i.v. 8 hourly for stress ulcer prophylaxis.
|
Drug: Ranitidine
In arm 1 Ranitidine was given in dose of 50mg i.v. 8 hourly for entire duration of ICU stay. |
Active Comparator: 2
In arm 2, Sucralfate was given in dose of 1gm via nasogastric tube 6 hourly for entire duration of ICU stay
|
Drug: Sucralfate
In arm 2, Sucralfate was given in dose of 1gm via nasogastric tube 6 hourly for entire duration of ICU stay |
- Occurence of ventilator associated pneumonia [ Time Frame: till discharge from ICU or death of Patient ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 13 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age greater than 12 years
- Those on mechanical ventilation for more than 48 hours.
Exclusion Criteria:
- Pre-existing pneumonia at the beginning of ventilation or
- Developing pneumonia within 48 hours of ventilation.
- Patients on oral antibiotics

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00702871
India | |
Maulana Azad Medical College and Lok Nayak Hospital | |
Delhi, India, 110002 |
Principal Investigator: | Rajiv Singla, M.D. | Maulana Azad Medical College and Lok Nayak Hospital, Delhi, India |
Responsible Party: | Dr Mradul K Daga, Maulana Azad Medical College and Lok Nayak Hospital, Delhi, India |
ClinicalTrials.gov Identifier: | NCT00702871 |
Other Study ID Numbers: |
403(7)/04MC(ACA)/Protocol/3499 |
First Posted: | June 20, 2008 Key Record Dates |
Last Update Posted: | June 20, 2008 |
Last Verified: | June 2008 |
Ventilator Associated Pneumonia antimicrobial susceptibility pattern stress ulcer prophylaxis |
Pneumonia, Ventilator-Associated Pneumonia Ulcer Disease Susceptibility Lung Diseases Respiratory Tract Diseases Respiratory Tract Infections Pathologic Processes Disease Attributes Cross Infection Infection |
Ranitidine Ranitidine bismuth citrate Sucralfate Anti-Ulcer Agents Gastrointestinal Agents Histamine H2 Antagonists Histamine Antagonists Histamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |